Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

A solid end to the week
Fri, 28 Aug Closing

After starting the morning session on a strong note, Indian stocks lost some steam during the afternoon session but managed to finish the day well above the dotted line. The BSE Sensex closed higher by 161 points, while the NSE-Nifty closed higher by 45 points. BSE Mid Cap and BSE Small Cap also closed in the green. Midcap was up by 0.3%, while Smallcap closed higher by 0.1%. Gains were largely seen in IT, auto, oil & gas and, while consumer durables, realty and banking stocks were at the receiving end.

Asian markets finished mixed as of the most recent closing prices. The Shanghai Composite gained 4.8% and the Nikkei 225 rose 3.03%. The Hang Seng lost 1.05%. European shares fell in early trade. The rupee was trading at 66.08 against the US$ at the time of writing.

According to a leading financial daily, UltraTech Cement is in discussion with Jaiprakash Associates for acquiring its 2.2 million tonne (MT) Bhilai unit. Both entities have approached SAIL for its nod for the deal as the domestic steel giant has a 26% stake in the facility. Earlier in December 2014, UltraTech Cement had acquired Jaiprakash Associates' two cement units and associated power plants in Madhya Pradesh for Rs 54 bn. The two units in Madhya Pradesh include clinker capacity of 2.1 million tonne and cement grinding capacity of 2.6 MT at Bela along with a captive power plant of 25 MW. In addition, 3.1 MT of clinker capacity and 2.3 MT of cement grinding capacity at Sidhi has also been sold along with a 155 MW power plant. The shares of Ultratech Cement ended the trading day up by 1.2% on the BSE.

Healthcare stocks finished the trading day with moderate losses with Glenmark Pharma and Sun Pharmaceuticals being the leading losers. According to a leading business daily, Lupin has received final approval from the United States Food and Drugs Administration (FDA) to market a generic version of AstraZeneca Pharmaceuticals LP's (AstraZeneca) Prilosec Delayed-Release capsules 40 mg. It is indicated for the short-term treatment of Duodenal Ulcer, Gastric Ulcer, treatment of Gastro Esophageal Reflux Disease (GERD), among others. Prilosec had annual US sales of US$ 185 m.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "A solid end to the week". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.